Fusion Pharmaceuticals Stock Fundamentals
Fusion Pharmaceuticals fundamentals help investors to digest information that contributes to Fusion Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Fusion Stock. The fundamental analysis module provides a way to measure Fusion Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Fusion Pharmaceuticals stock.
Fusion |
Fusion Pharmaceuticals Company Operating Margin Analysis
Fusion Pharmaceuticals' Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Current Fusion Pharmaceuticals Operating Margin | (54.04) % |
Most of Fusion Pharmaceuticals' fundamental indicators, such as Operating Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Fusion Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
CompetitionBased on the recorded statements, Fusion Pharmaceuticals has an Operating Margin of -54.0378%. This is 54.04% higher than that of the Biotechnology sector and 51.78% lower than that of the Health Care industry. The operating margin for all United States stocks is notably higher than that of the company.
Fusion Pharmaceuticals Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Fusion Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Fusion Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Fusion Pharmaceuticals competition to find correlations between indicators driving Fusion Pharmaceuticals's intrinsic value. More Info.Fusion Pharmaceuticals is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Fusion Pharmaceuticals' earnings, one of the primary drivers of an investment's value.Fusion Operating Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Fusion Pharmaceuticals' direct or indirect competition against its Operating Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Fusion Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Fusion Pharmaceuticals by comparing valuation metrics of similar companies.Fusion Pharmaceuticals is currently under evaluation in operating margin category among its peers.
Fusion Fundamentals
| Return On Equity | -0.47 | |||
| Return On Asset | -0.23 | |||
| Operating Margin | (54.04) % | |||
| Current Valuation | 1.69 B | |||
| Shares Outstanding | 85.06 M | |||
| Shares Owned By Insiders | 0.46 % | |||
| Shares Owned By Institutions | 86.80 % | |||
| Number Of Shares Shorted | 3.06 M | |||
| Price To Book | 8.13 X | |||
| Price To Sales | 874.50 X | |||
| Revenue | 2.07 M | |||
| Gross Profit | (57.43 M) | |||
| EBITDA | (97.89 M) | |||
| Net Income | (94.9 M) | |||
| Cash And Equivalents | 198.42 M | |||
| Cash Per Share | 4.57 X | |||
| Total Debt | 50.33 M | |||
| Debt To Equity | 0.08 % | |||
| Current Ratio | 17.89 X | |||
| Book Value Per Share | 2.85 X | |||
| Cash Flow From Operations | (81.8 M) | |||
| Short Ratio | 6.22 X | |||
| Earnings Per Share | (1.40) X | |||
| Target Price | 21.14 | |||
| Number Of Employees | 101 | |||
| Beta | -0.69 | |||
| Market Capitalization | 1.83 B | |||
| Total Asset | 285.84 M | |||
| Retained Earnings | (376.76 M) | |||
| Working Capital | 227.18 M | |||
| Net Asset | 285.84 M |
Pair Trading with Fusion Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Fusion Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Fusion Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Teradyne could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Teradyne when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Teradyne - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Teradyne to buy it.
The correlation of Teradyne is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Teradyne moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Teradyne moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Teradyne can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Other Consideration for investing in Fusion Stock
If you are still planning to invest in Fusion Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Fusion Pharmaceuticals' history and understand the potential risks before investing.
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios |